嚢胞性線維症患者における緑膿菌による慢性肺感染症の市場インサイト・疫学・市場予測(~2028)

◆英語タイトル:Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis - Market Insights, Epidemiology and Market Forecast – 2028
◆商品コード:DATA00109030
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2019年12月
◆ページ数:120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD6,250 ⇒換算¥700,000見積依頼/購入/質問フォーム
Global Site License(法人閲覧用)USD18,750 ⇒換算¥2,100,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis – Market Insights, Epidemiology and Market Forecast – 2028DelveInsight’s “Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis – Market Insights, Epidemiology and Market Forecast – 2028” report provides the detailed overview of the disease and in depth understanding of historical and forecasted Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis epidemiology. It highlights the existing treatment patterns, potential upcoming Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2017-2028.
Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan
Study Period: 2017-2028

Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Understanding and Treatment Algorithm
The Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis market report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in the US, Europe, and Japan are also provided in the report.

Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Epidemiology
This section provide the insights about historical and current Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis patient pool and forecasted trend for 7 major markets. It takes in to account the analysis of numerous studies, survey reports as well as KOL’s views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.

Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Product Profiles & Analysis
This part of the report encloses the detailed analysis of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.

Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Market Outlook
The Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight. Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Market Share by Therapies

This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.

Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Report Insights
• Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Patient Population
• Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Therapeutic Approaches
• Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Pipeline Analysis
• Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Market Size and Trends
• Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Market Opportunities
• Impact of upcoming Therapies in Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Report Key Strengths
• Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis 10 Year Forecast
• Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis 7MM Coverage
• Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Epidemiology Segmentation
• Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Drugs Uptake
• Highly Analyzed Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Market
• Key Cross Competition
Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Report Assessment
• Current Treatment Practices in Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
• Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Unmet Needs
• Detailed Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Pipeline Product Profiles
• Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Market Attractiveness
• Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Market Drivers and Barriers
Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis market
• Organize sales and marketing efforts by identifying the best opportunities for Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis market
• To understand the future market competition in the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis market.

*Please Note:* The report will be delivered in 7 – 10 business days upon order confirmation.

【レポートの目次】

1. Report Introduction
2. Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis Market Overview at a Glance
2.1. Market Share Distribution of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in 2017
2.2. Market Share Distribution of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in 2028
3. Disease Background and Overview: Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in 7MM
4.3. Total Prevalent Patient Population of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in 7MM – By Countries
5. Epidemiology of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
5.1.3. Sub-Type Specific cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis *Indication Specific
5.1.4. Sex- Specific Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis *Indication Specific
5.1.5. Diagnosed Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
5.1.6. Treatable Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
5.4.3. Sub-Type Specific cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis *
5.4.4. Sex- Specific Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis *
5.4.5. Diagnosed Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
5.4.6. Treatable Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
5.5.3. Sub-Type Specific cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis *
5.5.4. Sex- Specific Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis *
5.5.5. Diagnosed Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
5.5.6. Treatable Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
5.6.3. Sub-Type Specific cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis *
5.6.4. Sex- Specific Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis *
5.6.5. Diagnosed Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
5.6.6. Treatable Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
5.7.3. Sub-Type Specific cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis *
5.7.4. Sex- Specific Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis *
5.7.5. Diagnosed Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
5.7.6. Treatable Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
5.8.3. Sub-Type Specific cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis *
5.8.4. Sex- Specific Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis *
5.8.5. Diagnosed Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
5.8.6. Treatable Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
5.9.3. Sub-Type Specific cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis *
5.9.4. Sex- Specific Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis *
5.9.5. Diagnosed Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
5.9.6. Treatable Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis : 7MM Market Analysis
12.1. 7MM Market Size of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
12.2. 7MM Percentage Share of drugs marketed for Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis
12.3. 7MM Market Sales of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Products
13. Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in United States
13.1.2. Percentage Share of drugs marketed for Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in United States
13.1.3. Market Sales of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Germany
13.2.1.2. Percentage Share of drugs marketed for Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Germany
13.2.1.3. Market Sales of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in France
13.2.2.2. Percentage Share of drugs marketed for Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in France
13.2.2.3. Market Sales of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Italy
13.2.3.2. Percentage Share of drugs marketed for Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Italy
13.2.3.3. Market Sales of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Spain
13.2.4.2. Percentage Share of drugs marketed for Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Spain
13.2.4.3. Market Sales of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in United Kingdom
13.2.5.3. Market Sales of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Japan
13.3.2. Percentage Share of drugs marketed for Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Japan
13.3.3. Market Sales of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
Table 1: Total Prevalent/Incident Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in 7MM
Table 2: Total Prevalent/Incident Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in United States (2017-2028)
Table 4: Sub-Type Specific cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in United States (2017-2028)
Table 5: Sex- Specific Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in United States (2017-2028)
Table 6: Diagnosed Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in United States (2017-2028)
Table 7: Treatable Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in United States (2017-2028)
Table 8: Prevalent/Incident Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Germany (2017-2028)
Table 9: Sub-Type Specific cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Germany (2017-2028)
Table 10: Sex- Specific Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Germany (2017-2028)
Table 11: Diagnosed Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Germany (2017-2028)
Table 12: Treatable Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Germany (2017-2028)
Table 13: Prevalent/Incident Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in France (2017-2028)
Table 14: Sub-Type Specific cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in France (2017-2028)
Table 15: Sex- Specific Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in France (2017-2028)
Table 16: Diagnosed Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in France (2017-2028)
Table 17: Treatable Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in France (2017-2028)
Table 18: Prevalent/Incident Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Italy (2017-2028)
Table 19: Sub-Type Specific cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Italy (2017-2028)
Table 20: Sex- Specific Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Italy (2017-2028)
Table 21: Diagnosed Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Italy (2017-2028)
Table 22: Treatable Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Italy (2017-2028)
Table 23: Prevalent/Incident Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Spain (2017-2028)
Table 24: Sub-Type Specific cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Spain (2017-2028)
Table 25: Sex- Specific Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Spain (2017-2028)
Table 26: Diagnosed Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Spain (2017-2028)
Table 27: Treatable Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Spain (2017-2028)
Table 28: Prevalent/Incident Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in UK (2017-2028)
Table 29: Sub-Type Specific cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in UK (2017-2028)
Table 30: Sex- Specific Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in UK (2017-2028)
Table 31: Diagnosed Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in UK (2017-2028)
Table 32: Treatable Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in UK (2017-2028)
Table 33: Prevalent/Incident Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Japan (2017-2028)
Table 34: Sub-Type Specific cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Japan (2017-2028)
Table 35: Sex- Specific Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Japan (2017-2028)
Table 36: Diagnosed Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Japan (2017-2028)
Table 37: Treatable Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Japan (2017-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in USD MM (2017-2028)
Table 42:7MM- Market Share Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Table 43:7MM- Market Sales of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Table 44: United States-Market Size of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in USD MM (2017-2028)
Table 45: United States-Market Share Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Table 46: United States-Market Sales of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Table 47: Germany-Market Size of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in USD MM (2017-2028)
Table 48: Germany-Market Share Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Table 49: Germany-Market Sales of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Table 50: France-Market Size of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in USD MM (2017-2028)
Table 51: France-Market Share Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Table 52: France-Market Sales of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Table 53: Italy-Market Size of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in USD MM (2017-2028)
Table 54: Italy-Market Share Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Table 55: Italy-Market Sales of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Table 56: Spain-Market Size of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in USD MM (2017-2028)
Table 57: Spain-Market Share Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Table 58: Spain-Market Sales of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Table 59:UK-Market Size of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in USD MM (2017-2028)
Table 60:UK-Market Share Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Table 61:UK-Market Sales of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Table 62: Japan-Market Size of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in USD MM (2017-2028)
Table 63: Japan-Market Share Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Table 64: Japan-Market Sales of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Figure 1: Total Prevalent/Incident Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in 7MM
Figure 2: Total Prevalent/Incident Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in United States (2017-2028)
Figure 4: Sub-Type Specific cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in United States (2017-2028)
Figure 5: Sex- Specific Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in United States (2017-2028)
Figure 6: Diagnosed Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in United States (2017-2028)
Figure 7: Treatable Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in United States (2017-2028)
Figure 8: Prevalent/Incident Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Germany (2017-2028)
Figure 9: Sub-Type Specific cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Germany (2017-2028)
Figure 10: Sex- Specific Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Germany (2017-2028)
Figure 11: Diagnosed Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Germany (2017-2028)
Figure 12: Treatable Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Germany (2017-2028)
Figure 13: Prevalent/Incident Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in France (2017-2028)
Figure 14: Sub-Type Specific cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in France (2017-2028)
Figure 15: Sex- Specific Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in France (2017-2028)
Figure 16: Diagnosed Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in France (2017-2028)
Figure 17: Treatable Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in France (2017-2028)
Figure 18: Prevalent/Incident Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Italy (2017-2028)
Figure 19: Sub-Type Specific cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Italy (2017-2028)
Figure 20: Sex- Specific Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Italy (2017-2028)
Figure 21: Diagnosed Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Italy (2017-2028)
Figure 22: Treatable Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Italy (2017-2028)
Figure 23: Prevalent/Incident Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Spain (2017-2028)
Figure 24: Sub-Type Specific cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Spain (2017-2028)
Figure 25: Sex- Specific Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Spain (2017-2028)
Figure 26: Diagnosed Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Spain (2017-2028)
Figure 27: Treatable Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Spain (2017-2028)
Figure 28: Prevalent/Incident Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in UK (2017-2028)
Figure 29: Sub-Type Specific cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in UK (2017-2028)
Figure 30: Sex- Specific Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in UK (2017-2028)
Figure 31: Diagnosed Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in UK (2017-2028)
Figure 32: Treatable Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in UK (2017-2028)
Figure 33: Prevalent/Incident Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Japan (2017-2028)
Figure 34: Sub-Type Specific cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Japan (2017-2028)
Figure 35: Sex- Specific Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Japan (2017-2028)
Figure 36: Diagnosed Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Japan (2017-2028)
Figure 37: Treatable Cases of the Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in Japan (2017-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in USD MM (2017-2028)
Figure 42:7MM- Market Share Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Figure 43:7MM- Market Sales of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Figure 44: United States-Market Size of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in USD MM (2017-2028)
Figure 45: United States-Market Share Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Figure 46: United States-Market Sales of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Figure 47: Germany-Market Size of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in USD MM (2017-2028)
Figure 48: Germany-Market Share Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Figure 49: Germany-Market Sales of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Figure 50: France-Market Size of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in USD MM (2017-2028)
Figure 51: France-Market Share Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Figure 52: France-Market Sales of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Figure 53: Italy-Market Size of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in USD MM (2017-2028)
Figure 54: Italy-Market Share Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Figure 55: Italy-Market Sales of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Figure 56: Spain-Market Size of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in USD MM (2017-2028)
Figure 57: Spain-Market Share Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Figure 58: Spain-Market Sales of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Figure 59:UK-Market Size of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in USD MM (2017-2028)
Figure 60:UK-Market Share Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Figure 61:UK-Market Sales of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Figure 62: Japan-Market Size of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis in USD MM (2017-2028)
Figure 63: Japan-Market Share Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)
Figure 64: Japan-Market Sales of Chronic Pulmonary Infections due to Pseudomonas Aeruginosa in patients with Cystic Fibrosis by Therapies in USD MM (2017-2028)



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[嚢胞性線維症患者における緑膿菌による慢性肺感染症の市場インサイト・疫学・市場予測(~2028)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆